The Molecular Oncology Almanac: Assertion Details

Assertion: Resistance to Gefitinib (in Non-Small Cell Lung Cancer)
Clinical evidence

Copy Number: CRKL Amplification

CRKL amplification was observed in an EGFR inhibitor resistant tumor after researchers observed that cells from gefitinib-sensitive cell line (HCC827) overexpressing CRKL became resistant to gefitinib relative to controls.

Citations:

Cheung HW, Du J, Boehm JS, et al. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 2011;1(7):608-25.

Assertion: Resistance to Gefitinib (in Non-Small Cell Lung Cancer) Clinical evidence

Clinical evidence

Assertion: Resistance to Gefitinib (in Non-Small Cell Lung Cancer)
Clinical evidence